Bradykinin activates ADP-ribosyl cyclase in neuroblastoma cells: intracellular concentration decrease in NAD and increase in cyclic ADP-ribose

FEBS Lett. 2006 Sep 4;580(20):4857-60. doi: 10.1016/j.febslet.2006.07.084. Epub 2006 Aug 8.

Abstract

ADP-ribosyl cyclase activity in the crude membrane fraction of neuroblastomaxglioma NGPM1-27 hybrid cells was measured by monitoring [(3)H] cyclic ADP-ribose (cADPR) formation from [(3)H] NAD(+). Bradykinin (BK) at 100nM increased ADP-ribosyl cyclase activity by about 2.5-fold. Application of 300nM BK to living NGPM1-27 cells decreased NAD(+) to 78% of the prestimulation level at 30s. In contrast, intracellular cADPR concentrations were increased by 2-3-fold during the period from 30 to 120s after the same treatment. Our results suggest that cADPR is one of the second messengers downstream of B(2) BK receptors.

MeSH terms

  • ADP-ribosyl Cyclase / metabolism*
  • Animals
  • Bradykinin / pharmacology*
  • Cell Line, Tumor / drug effects*
  • Cell Membrane / chemistry
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cyclic ADP-Ribose / metabolism*
  • Hybrid Cells / cytology
  • Hybrid Cells / drug effects
  • Mice
  • NAD / metabolism*
  • Neuroblastoma
  • Rats
  • Second Messenger Systems / physiology
  • Vasodilator Agents / pharmacology*

Substances

  • Vasodilator Agents
  • NAD
  • Cyclic ADP-Ribose
  • ADP-ribosyl Cyclase
  • Bradykinin